Electroconvulsive therapy and clozapine in adolescents with schizophrenia spectrum disorders: Is it a safe and effective combination?

Journal of Clinical Psychopharmacology

Volumn 32, Issue 6, 2012, Pages 756-766

  Flamarique, Itziar ^a   Castro Fornieles, Josefina ^a,b,c,d   Garrido, Juan Miguel ^e   De La Serna, Elena ^a,b   Pons, Alexandre ^a,b,d,e   Bernardo, Miguel ^a,b,c,d,e   Baeza, Inmaculada ^a,b,c,e  

^a HOSPITAL CLÍNIC   (Spain)

^b CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED DE SALUD MENTAL CIBERSAM   (Spain)

^c INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

^d UNIVERSITY OF BARCELONA   (Spain)

^e Hosp Clin Univ   (Spain)

Author keywords

adolescents; clozapine; electroconvulsive therapy; psychosis; schizophrenia

Indexed keywords

AMISULPRIDE; ARIPIPRAZOLE; CITALOPRAM; CLOMIPRAMINE; CLOZAPINE; DIAZEPAM; FLUOXETINE; HALOPERIDOL; LITHIUM; LORAZEPAM; NORTRIPTYLINE; OLANZAPINE; OXCARBAZEPINE; PALIPERIDONE; PERPHENAZINE; PROPOFOL; QUETIAPINE; RISPERIDONE; SERTRALINE; THIOPENTAL; VALPROIC ACID; ZIPRASIDONE;

ADOLESCENT; ADULT; AGITATION; ARTICLE; CATATONIA; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; CLINICAL GLOBAL IMPRESSION SCALE; CONTROLLED STUDY; DSM-IV-TR; ELECTROCONVULSIVE THERAPY; ELECTROENCEPHALOGRAPHY; FEMALE; FOLLOW UP; HEADACHE; HOSPITAL READMISSION; HUMAN; MALE; MYALGIA; PATIENT ASSESSMENT; PATIENT MONITORING; PATIENT SAFETY; POSITIVE AND NEGATIVE SYNDROME SCALE; PRIORITY JOURNAL; RESTLESSNESS; SCHIZOPHRENIA; SEIZURE; SUICIDAL BEHAVIOR; TACHYCARDIA; TREATMENT DURATION;

ADOLESCENT; ANTIPSYCHOTIC AGENTS; CLOZAPINE; COMBINED MODALITY THERAPY; ELECTROCARDIOGRAPHY; ELECTROCONVULSIVE THERAPY; FEMALE; FOLLOW-UP STUDIES; HOSPITALIZATION; HUMANS; MALE; RETROSPECTIVE STUDIES; SCHIZOPHRENIA; SEIZURES; TREATMENT OUTCOME;

EID: 84870253021     PISSN: 02710749     EISSN: 1533712X     Source Type: Journal    
DOI: 10.1097/JCP.0b013e318270e2c7     Document Type: Article

References (87)

1. Hollis C. Adult outcomes of child- and adolescent-onset schizophrenia: Diagnostic stability and predictive validity. Am J Psychiatry. 2000;157:1652-1659.
2. Hafner H, Nowotny B. Epidemiology of early-onset schizophrenia. Eur Arch Psychiatry Clin Neurosci. 1995;245:80-92.
3. Mattai AK, Hill JL, Lenroot RK. Treatment of early-onset schizophrenia. Curr Opin Psychiatry. 2010;23:304-310.
4. Kumra S, Oberstar JV, Sikich L, et al. Efficacy and tolerability of second-generation antipsychotics in children and adolescents with schizophrenia. Schizophr Bull. 2008;34:60-71. (Pubitemid 350262286)
5. Kane JM. Clinical efficacy of clozapine in treatment-refractory schizophrenia: An overview. Br J Psychiatry Suppl. 1992;17:41-45.
6. Kane J, Honigfeld G, Singer J, et al. Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Arch Gen Psychiatry. 1988;45:789-796.
7. Agid O, Remington G, Kapur S, et al. Early use of clozapine for poorly responding first-episode psychosis. J Clin Psychopharmacol. 2007;27:369-373. (Pubitemid 47075508)
8. Conley RR, Love RC, Kelly DL, et al. Rehospitalization rates of patients recently discharged on a regimen of risperidone or clozapine. Am J Psychiatry. 1999;156:863-868. (Pubitemid 29260340)
9. Conley RR, Kelly DL, Love RC, et al. Rehospitalization risk with second-generation and depot antipsychotics. Ann Clin Psychiatry. 2003;15:23-31. (Pubitemid 36723638)
10. Lin CH, Lin SC, Chen MC, et al. Comparison of time to rehospitalization among schizophrenic patients discharged on typical antipsychotics, clozapine or risperidone. J Chin Med Assoc. 2006;69:264-269.
11. Castro AP, Elkis H. Rehospitalization rates of patients with schizophrenia discharged on haloperidol, risperidone or clozapine. Rev Bras Psiquiatr. 2007;29:207-212.
12. Herceg M, Jukic V, Vidovic D, et al. Two-year rehospitalization rates of patients with newly diagnosed or chronic schizophrenia on atypical or typical antipsychotic drugs: Retrospective cohort study. Croat Med J. 2008;49:215-223. (Pubitemid 351669462)
13. Werneck AP, Hallak JC, Nakano E, et al. Time to rehospitalization in patients with schizophrenia discharged on first generation antipsychotics, non-clozapine second generation antipsychotics, or clozapine. Psychiatry Res. 2011;188:315-319.
14. Pollack S, Woerner MG, Howard A, et al. Clozapine reduces rehospitalization among schizophrenia patients. Psychopharmacol Bull. 1998;34:89-92. (Pubitemid 28176307)
15. England ML, Ongur D, Konopaske GT, et al. Catatonia in psychotic patients: Clinical features and treatment response. J Neuropsychiatry Clin Neurosci. 2011;23:223-226.
16. Dursun SM, Hallak JE, Haddad P, et al. Clozapine monotherapy for catatonic schizophrenia: Should clozapine be the treatment of choice, with catatonia rather than psychosis as the main therapeutic index? J Psychopharmacol. 2005;19:432-433. (Pubitemid 41003143)
17. Lausberg H, Hellweg R. [''Catatonic dilemma''. Therapy with lorazepam and clozapine]. Nervenarzt. 1998;69:818-822. (Pubitemid 28419383)
18. Fraguas D, Correll CU, Merchan-Naranjo J, et al. Efficacy and safety of second-generation antipsychotics in children and adolescents with psychotic and bipolar spectrum disorders: Comprehensive review of prospective head-to-head and placebo-controlled comparisons. Eur Neuropsychopharmacol. 2011;21:621-645.
19. Shaw P, Sporn A, Gogtay N, et al. Childhood-onset schizophrenia: A double-blind, randomized clozapine-olanzapine comparison. Arch Gen Psychiatry. 2006;63:721-730.
20. Kranzler H, Roofeh D, Gerbino-Rosen G, et al. Clozapine: Its impact on aggressive behavior among children and adolescents with schizophrenia. J Am Acad Child Adolesc Psychiatry. 2005;44:55-63. (Pubitemid 40019200)
21. Sporn AL, Vermani A, Greenstein DK, et al. Clozapine treatment of childhood-onset schizophrenia: Evaluation of effectiveness, adverse effects, and long-term outcome. J Am Acad Child Adolesc Psychiatry. 2007;46:1349-1356. (Pubitemid 47462194)
22. Gogtay N, Rapoport J. Clozapine use in children and adolescents. Expert Opin Pharmacother. 2008;9:459-465. (Pubitemid 351291789)
23. Freudenreich O, Weiner RD, McEvoy JP. Clozapine-induced electroencephalogram changes as a function of clozapine serum levels. Biol Psychiatry. 1997;42:132-137. (Pubitemid 27276076)
24. Sajatovic M, Meltzer HY. Clozapine-induced myoclonus and generalized seizures. Biol Psychiatry. 1996;39:367-370. (Pubitemid 26122563)
25. Chandrasekaran PK. Agranulocytosis monitoring with clozapine patients: To follow guidelines or to attempt therapeutic controversies? Singapore Med J. 2008;49:96-99. (Pubitemid 351488542)
26. Munro J, O'Sullivan D, Andrews C, et al. Active monitoring of 12,760 clozapine recipients in the UK and Ireland. Beyond pharmacovigilance. Br J Psychiatry. 1999;175:576-580.
27. Atkin K, Kendall F, Gould D, et al. Neutropenia and agranulocytosis in patients receiving clozapine in the UK and Ireland. Br J Psychiatry. 1996;169:483-488.
28. Ragonnet L, Abadie P, Dollfus S. Use of clozapine in an adolescent with refractory first-episode psychosis and neutropenia. J Clin Psychopharmacol. 2010;30:336-338.
29. Chanpattana W, Andrade C. ECT for treatment-resistant schizophrenia: A response from the Far East to the UK. NICE report. J ECT. 2006;22:4-12. (Pubitemid 44491123)
30. Baeza I, Flamarique I, Garrido JM, et al. Clinical experience using electroconvulsive therapy in adolescents with schizophrenia spectrum disorders. J Child Adolesc Psychopharmacol. 2010;20:205-209.
31. Baeza I, Pons A, Horga G, et al. Electroconvulsive therapy in early adolescents with schizophrenia spectrum disorders. J ECT. 2009;25:278-279.
32. Suzuki K, Awata S, Takano T, et al. Improvement of psychiatric symptoms after electroconvulsive therapy in young adults with intractable first-episode schizophrenia and schizophreniform disorder. Tohoku J Exp Med. 2006;210:213-220. (Pubitemid 44697264)
33. Ghaziuddin N, Kutcher SP, Knapp P, et al. Practice parameter for use of electroconvulsive therapy with adolescents. J Am Acad Child Adolesc Psychiatry. 2004;43:1521-1539.
34. Domenech C, Bernardo M, Arrufat F. [Electroconvulsive therapy in children and adolescents: A review of the literature]. Med Clin (Barc). 2004;122:349-354. (Pubitemid 38667633)
35. Bloch Y, Levcovitch Y, Bloch AM, et al. Electroconvulsive therapy in adolescents: Similarities to and differences from adults. J Am Acad Child Adolesc Psychiatry. 2001;40:1332-1336. (Pubitemid 32995802)
36. Walter G, Rey JM, Mitchell PB. Practitioner review: Electroconvulsive therapy in adolescents. J Child Psychol Psychiatry. 1999;40:325-334. (Pubitemid 29108100)
37. Cohen D, Paillere-Martinot ML, Basquin M. Use of electroconvulsive therapy in adolescents. Convuls Ther. 1997;13:25-31. (Pubitemid 27204015)
38. Moise FN, Petrides G. Case study: Electroconvulsive therapy in adolescents. J Am Acad Child Adolesc Psychiatry. 1996;35:312-318. (Pubitemid 26072288)
39. Schneekloth TD, Rummans TA, Logan KM. Electroconvulsive therapy in adolescents. Convuls Ther. 1993;9:158-166. (Pubitemid 23284747)
40. Bloch Y, Sobol D, Levkovitz Y, et al. Reasons for referral for electroconvulsive therapy: A comparison between adolescents and adults. Australas Psychiatry. 2008;16:191-194. (Pubitemid 351890612)
41. Taieb O, Flament MF, Chevret S, et al. Clinical relevance of electroconvulsive therapy (ECT) in adolescents with severe mood disorder: Evidence from a follow-up study. Eur Psychiatry. 2002;17:206-212. (Pubitemid 34987823)
42. Johanson A, Gustafson L, Risberg J, et al. Long-term follow-up in depressed patients treated with electroconvulsive therapy. J ECT. 2005;21:214-220. (Pubitemid 41772222)
43. de la Serna Elena, Flamarique I, Castro-Fornieles J, et al. Two-year follow-up of cognitive functions in schizophrenia spectrum disorders of adolescent patients treated with ECT. J Child Adolesc Psychopharmacol. 2011;21:611-619.
44. Cohen D, Taieb O, Flament M, et al. Absence of cognitive impairment at long-term follow-up in adolescents treated with ECT for severe mood disorder. Am J Psychiatry. 2000;157:460-462. (Pubitemid 30145937)
45. Rey JM, Walter G. Half a century of ECT use in young people. Am J Psychiatry. 1997;154:595-602. (Pubitemid 27197590)
46. Fink M. Clozapine and electroconvulsive therapy. Arch Gen Psychiatry. 1990;47:290-291.
47. Konig P, Glatter-Gotz U. Combined electroconvulsive and neuroleptic therapy in schizophrenia refractory to neuroleptics. Schizophr Res. 1990;3:351-354. (Pubitemid 20383971)
48. Frankenburg FR, Suppes T, McLean PE. Combined clozapine and electroconvulsive therapy. Convuls Ther. 1993;9:176-180. (Pubitemid 23284749)
49. Havaki-Kontaxaki BJ, Ferentinos PP, Kontaxakis VP, et al. Concurrent administration of clozapine and electroconvulsive therapy in clozapine-resistant schizophrenia. Clin Neuropharmacol. 2006; 29:52-56. (Pubitemid 44378611)
50. Kupchik M, Spivak B, Mester R, et al. Combined electroconvulsive- clozapine therapy. Clin Neuropharmacol. 2000;23:14-16. (Pubitemid 30090406)
51. Nothdurfter C, Eser D, Schule C, et al. The influence of concomitant neuroleptic medication on safety, tolerability and clinical effectiveness of electroconvulsive therapy. World J Biol Psychiatry. 2006;7:162-170. (Pubitemid 44132542)
52. Masoudzadeh A, Khalilian AR. Comparative study of clozapine, electroshock and the combination of ECT with clozapine in treatment-resistant schizophrenic patients. Pak J Biol Sci. 2007;10:4287-4290. (Pubitemid 350158596)
53. Hustig H, Onilov R. ECT rekindles pharmacological response in schizophrenia. Eur Psychiatry. 2009;24:521-525.
54. Green AI, Zalma A, Berman I, et al. Clozapine following ECT: A two-step treatment. J Clin Psychiatry. 1994;55:388-390. (Pubitemid 24337994)
55. James DV, Gray NS. Elective combined electroconvulsive and clozapine therapy. Int Clin Psychopharmacol. 1999;14:69-72. (Pubitemid 29149864)
56. Hung YY, Yang PS, Huang TL. Clozapine in schizophrenia patients with recurrent catatonia: Report of two cases. Psychiatry Clin Neurosci. 2006;60:256-258.
57. Gazdag G, Barna I, Ivanyi Z, et al. The impact of neuroleptic medication on seizure threshold and duration in electroconvulsive therapy. Ideggyogy Sz. 2004;57:385-390.
58. Bloch Y, Pollack M, Mor I. Should the administration of ECT during clozapine therapy be contraindicated? Br J Psychiatry. 1996;169:253-254. (Pubitemid 26291614)
59. Poyurovsky M, Weizman A. Safety and effectiveness of combined ECT and clozapine in treatment-resistant mania. Eur Psychiatry. 1996;11:319-321. (Pubitemid 26354552)
60. Masiar SJ, Johns CA. ECT following clozapine. Br J Psychiatry. 1991;158:135-136.:135-136.
61. Safferman AZ, Munne R. Combining clozapine with ECT. Convuls Ther. 1992;8:141-143.
62. Klapheke MM. Follow-up on clozapine and ECT. Convuls Ther. 1991;7:303-305.
63. Landy DA. Combined use of clozapine and electroconvulsive therapy. Convuls Ther. 1991;7:218-221.
64. Keller S, Drexler H, Lichtenberg P. Very high-dose clozapine and electroconvulsive therapy combination treatment in a patient with schizophrenia. J ECT. 2009;25:280-281.
65. Braga RJ, Petrides G. The combined use of electroconvulsive therapy and antipsychotics in patients with schizophrenia. J ECT. 2005;21:75-83. (Pubitemid 40800031)
66. Kho KH, Blansjaar BA, de VS, et al. Electroconvulsive therapy for the treatment of clozapine nonresponders suffering from schizophreniaVan open label study. Eur Arch Psychiatry Clin Neurosci. 2004;254:372-379. (Pubitemid 40192992)
67. Kales HC, Dequardo JR, Tandon R. Combined electroconvulsive therapy and clozapine in treatment-resistant schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry. 1999;23:547-556. (Pubitemid 29274223)
68. Benatov R, Sirota P, Megged S. Neuroleptic-resistant schizophrenia treated with clozapine and ECT. Convuls Ther. 1996;12:117-121. (Pubitemid 26162470)
69. Cardwell BA, Nakai B. Seizure activity in combined clozapine and ECT: A retrospective view. Convuls Ther. 1995;11:110-113.
70. Bundy BD, Hewer W, Andres FJ, et al. Influence of anesthetic drugs and concurrent psychiatric medication on seizure adequacy during electroconvulsive therapy. J Clin Psychiatry. 2010;71:775-777.
71. Petrides G, Braga RJ, Fink M, et al. Seizure threshold in a large sample: Implications for stimulus dosing strategies in bilateral electroconvulsive therapy: A report from CORE. J ECT. 2009;25:232-237.
72. Poulet E, Auriacombe M, Tignol J. [Seizure threshold and ECT. Importance for good clinical practice of ECT. A review of literature]. Encephale. 2003;29:99-107. (Pubitemid 36565980)
73. Sackeim HA. The anticonvulsant hypothesis of the mechanisms of action of ECT: Current status. J ECT. 1999;15:5-26. (Pubitemid 29318091)
74. Bauer J, Hageman I, Dam H, et al. Comparison of propofol and thiopental as anesthetic agents for electroconvulsive therapy: A randomized, blinded comparison of seizure duration, stimulus charge, clinical effect, and cognitive side effects. J ECT. 2009;25:85-90.
75. Consoli A, Boulicot V, Cornic F, et al. Moderate clinical improvement with maintenance ECT in a 17-year-old boy with intractable catatonic schizophrenia. Eur Child Adolesc Psychiatry. 2009;18:250-254.
76. Mane A, Baeza I, Morer A, et al. Neuroleptic malignant syndrome associated with risperidone in a male with early-onset schizophrenia. J Child Adolesc Psychopharmacol. 2005;15:844-845. (Pubitemid 43042976)
77. Mankad Mehul V, Beyer John L, Weiner Richard D, et al. Clinical Manual of Electroconvulsive Therapy. Arlington, VA: American Psychiatric Publishing; 2010.
78. Trevino K, McClintock SM, Husain MM. A review of continuation electroconvulsive therapy: Application, safety, and efficacy. J ECT. 2010;26:186-195.
79. Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull. 1987;13:261-276. (Pubitemid 18039085)
80. Peralta V, Cuesta MJ. Psychometric properties of the positive and negative syndrome scale (PANSS) in schizophrenia. Psychiatry Res. 1994;53:31-40. (Pubitemid 24266119)
81. Guy W. Clinical Global Impression. ECDEU Assessment Manual for Psychopharmacology, revised National Institute of Mental Health. Rockville: 1976.
82. Schooler N, Rabinowitz J, Davidson M, et al. Risperidone and haloperidol in first-episode psychosis: A long-term randomized trial. Am J Psychiatry. 2005;162:947-953. (Pubitemid 40676208)
83. Spina E, Avenoso A, Facciola G, et al. Relationship between plasma concentrations of clozapine and norclozapine and therapeutic response in patients with schizophrenia resistant to conventional neuroleptics. Psychopharmacology (Berl). 2000;148:83-89. (Pubitemid 30062476)
84. Bondolfi G, Dufour H, Patris M, et al. Risperidone versus clozapine in treatment-resistant chronic schizophrenia: A randomized double-blind study. The Risperidone Study Group. Am J Psychiatry. 1998;155: 499-504. (Pubitemid 28207445)
85. Young CR, Bowers MB Jr, Mazure CM. Management of the adverse effects of clozapine. Schizophr Bull. 1998;24:381-390. (Pubitemid 28378223)
86. Ucok A, Cakr S. Electroconvulsive therapy in first-episode schizophrenia. J ECT. 2006;22:38-42. (Pubitemid 44491129)
87. Essock SM, HargreavesWA, Covell NH, et al. Clozapine's effectiveness for patients in state hospitals: Results from a randomized trial. Psychopharmacol Bull. 1996;32:683-697. (Pubitemid 26428274)